355. Beadle B. M., Guadagnolo B. A., Ballo M. T., Lee J. E., Gershenwald J. E., Cormier J. N., Mansfield P. F., Ross M. I., Zagars G. K. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma // Int J Radiat Oncol Biol Phys. ‒ 2009. ‒ T. 73, № 5. ‒ C. 1376-82.
356. Bibault J. E., Dewas S., Mirabel X., Mortier L., Penel N., Vanseymortier L., Lartigau E. Adjuvant radiation therapy in metastatic lymph nodes from melanoma // Radiat Oncol. ‒ 2011. ‒ T. 6. ‒ C. 12.
357. Adams G., Foote M., Brown S., Burmeister B. Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques // Melanoma Res. ‒ 2017. ‒ T. 27, № 1. ‒ C. 50-56.
358. Mattes M. D., Zhou Y., Berry S. L., Barker C. A. Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer // Radiat Oncol J. ‒ 2016. ‒ T. 34, № 2. ‒ C. 145-55.
359. The TNM classification of malignant tumours 8th edition /. ‒: Wiley-Blackwell, 2009.
360. Eggermont A. M., Suciu S., Santinami M., Testori A., Kruit W. H., Marsden J., Punt C. J., Sales F., Gore M., Mackie R., Kusic Z., Dummer R., Hauschild A., Musat E., Spatz A., Keilholz U. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial // Lancet. ‒ 2008. ‒ T. 372, № 9633. ‒ C. 117-26.
361. Mocellin S., Pasquali S., Rossi C. R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis // J Natl Cancer Inst. ‒ 2010. ‒ T. 102, № 7. ‒ C. 493-501.
362. Ives N. J., Suciu S., Eggermont A. M. M., Kirkwood J., Lorigan P., Markovic S. N., Garbe C., Wheatley K., International Melanoma Meta-Analysis Collaborative G. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis // Eur J Cancer. ‒ 2017. ‒ T. 82. ‒ C. 171-183.
363. Luke J. J., Rutkowski P., Queirolo P., Del Vecchio M., Mackiewicz J., Chiarion-Sileni V., de la Cruz Merino L., Khattak M. A., Schadendorf D., Long G. V., Ascierto P. A., Mandala M., De Galitiis F., Haydon A., Dummer R., Grob J. J., Robert C., Carlino M. S., Mohr P., Poklepovic A., Sondak V. K., Scolyer R. A., Kirkwood J. M., Chen K., Diede S. J., Ahsan S., Ibrahim N., Eggermont A. M. M., Investigators K.-. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial // Lancet. ‒ 2022.10.1016/S0140-6736(22)00562-1.
364. Pehamberger H., Soyer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Aubock J., Fritsch P., Kerl H., Wolff K. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group // J Clin Oncol. ‒ 1998. ‒ T. 16, № 4. ‒ C. 1425-9.
365. Mocellin S., Lens M. B., Pasquali S., Pilati P., Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma // Cochrane Database Syst Rev. ‒ 2013.10.1002/14651858.CD008955.pub2 № 6. ‒ C. CD008955.
366. Karamfilov T., Wollina U., Hipler U. C., Graefe T., Schreiber G. Effects of adjuvant interferon-alpha low-dose therapy in melanoma patients on serum inhibin B // J Dermatol. ‒ 2000. ‒ T. 27, № 10. ‒ C. 639-42.
367. Lala M., Li T. R., de Alwis D. P., Sinha V., Mayawala K., Yamamoto N., Siu L. L., Chartash E., Aboshady H., Jain L. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation // Eur J Cancer. ‒ 2020. ‒ T. 131. ‒ C. 68-75.
368. Zhao X., Suryawanshi S., Hruska M., Feng Y., Wang X., Shen J., Vezina H. E., McHenry M. B., Waxman I. M., Achanta A., Bello A., Roy A., Agrawal S. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors // Ann Oncol. ‒ 2017. ‒ T. 28, № 8. ‒ C. 2002-2008.
369. Long G. V., Tykodi S. S., Schneider J. G., Garbe C., Gravis G., Rashford M., Agrawal S., Grigoryeva E., Bello A., Roy A., Rollin L., Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer // Ann Oncol. ‒ 2018. ‒ T. 29, № 11. ‒ C. 2208-2213.
370. Luke J. J., Ascierto P. A., Carlino M. S., Gershenwald J. E., Grob J. J., Hauschild A., Kirkwood J. M., Long G. V., Mohr P., Robert C., Ross M., Scolyer R. A., Yoon C. H., Poklepovic A., Rutkowski P., Anderson J. R., Ahsan S., Ibrahim N., AM M. E. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma // Future Oncol. ‒ 2020. ‒ T. 16, № 3. ‒ C. 4429-4438.
371. Kirkwood J. M., Del Vecchio M., Weber J., Hoeller C., Grob J. J., Mohr P., Loquai C., Dutriaux C., Chiarion-Sileni V., Mackiewicz J., Rutkowski P., Arenberger P., Quereux G., Meniawy T. M., Ascierto P. A., Menzies A. M., Durani P., Lobo M., Campigotto F., Gastman B., Long G. V. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial // Nat Med. ‒ 2023. ‒ T. 29, № 11. ‒ C. 2835-2843.
372. Barth A., Morton D. L. The role of adjuvant therapy in melanoma management // Cancer. ‒ 1995. ‒ T. 75, № 2 Suppl. ‒ C. 726-34.
373. Chiarion-Sileni V., Del Bianco P., Romanini A., Guida M., Paccagnella A., Dalla Palma M., Naglieri E., Ridolfi R., Silvestri B., Michiara M., De Salvo G. L. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874] // BMC Cancer. ‒ 2006. ‒ T. 6. ‒ C. 44.